Shattuck Labs Competitors

Galapagos (NASDAQ:GLPG) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Galapagos and Shattuck Labs, as reported by MarketBeat.com.

Galapagos presently has a consensus price target of $143.7273, suggesting a potential upside of 82.05%. Shattuck Labs has a consensus price target of $45.60, suggesting a potential upside of 44.85%. Given Galapagos' higher possible upside, analysts clearly believe Galapagos is more favorable than Shattuck Labs.

Profitability

This table compares Galapagos and Shattuck Labs' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Galapagos and Shattuck Labs' gross revenue, earnings per share (EPS) and valuation.

Galapagos has higher revenue and earnings than Shattuck Labs.

Summary

Shattuck Labs beats Galapagos on 5 of the 9 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biohaven Pharmaceutical and Shattuck Labs, as provided by MarketBeat.

Biohaven Pharmaceutical presently has a consensus target price of $96.4545, suggesting a potential upside of 29.37%. Shattuck Labs has a consensus target price of $45.60, suggesting a potential upside of 44.85%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Biohaven Pharmaceutical.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Biohaven Pharmaceutical and Shattuck Labs' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Shattuck Labs' revenue, earnings per share and valuation.

Summary

Shattuck Labs beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Shattuck Labs (NASDAQ:STTK) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Shattuck Labs and Sage Therapeutics, as reported by MarketBeat.com.

Shattuck Labs presently has a consensus target price of $45.60, suggesting a potential upside of 44.85%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 14.36%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe Shattuck Labs is more favorable than Sage Therapeutics.

Profitability

This table compares Shattuck Labs and Sage Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Shattuck Labs and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Shattuck Labs has higher earnings, but lower revenue than Sage Therapeutics.

Summary

Shattuck Labs beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Shattuck Labs (NASDAQ:STTK) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares Shattuck Labs and Hutchison China MediTech's top-line revenue, earnings per share and valuation.

Shattuck Labs has higher earnings, but lower revenue than Hutchison China MediTech.

Profitability

This table compares Shattuck Labs and Hutchison China MediTech's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Shattuck Labs and Hutchison China MediTech, as reported by MarketBeat.com.

Shattuck Labs presently has a consensus price target of $45.60, suggesting a potential upside of 44.85%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 37.65%. Given Shattuck Labs' higher probable upside, research analysts plainly believe Shattuck Labs is more favorable than Hutchison China MediTech.

Institutional and Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Shattuck Labs (NASDAQ:STTK) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Shattuck Labs and I-Mab's gross revenue, earnings per share and valuation.

Shattuck Labs has higher earnings, but lower revenue than I-Mab.

Profitability

This table compares Shattuck Labs and I-Mab's net margins, return on equity and return on assets.

Institutional & Insider Ownership

16.6% of I-Mab shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Shattuck Labs and I-Mab, as provided by MarketBeat.com.

Shattuck Labs presently has a consensus price target of $45.60, indicating a potential upside of 44.85%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 22.81%. Given Shattuck Labs' higher possible upside, analysts clearly believe Shattuck Labs is more favorable than I-Mab.

Shattuck Labs (NASDAQ:STTK) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Shattuck Labs and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Shattuck Labs.

Insider and Institutional Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Shattuck Labs and Arena Pharmaceuticals, as provided by MarketBeat.com.

Shattuck Labs presently has a consensus price target of $45.60, indicating a potential upside of 44.85%. Arena Pharmaceuticals has a consensus price target of $92.80, indicating a potential upside of 38.34%. Given Shattuck Labs' higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Shattuck Labs and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arena Pharmaceuticals beats Shattuck Labs on 4 of the 7 factors compared between the two stocks.